Exploring High Insider Ownership Growth Companies On SEHK

In This Article:

Amid a backdrop of fluctuating global markets and mixed economic signals, the Hong Kong market has shown resilience, with the Hang Seng Index recently marking a notable rise. This environment sets an intriguing stage for exploring growth companies in Hong Kong that boast high insider ownership—a characteristic often linked to strong corporate governance and alignment of interests between shareholders and management.

Top 10 Growth Companies With High Insider Ownership In Hong Kong

Name

Insider Ownership

Earnings Growth

iDreamSky Technology Holdings (SEHK:1119)

20.1%

104.1%

New Horizon Health (SEHK:6606)

16.6%

62.3%

Fenbi (SEHK:2469)

32.2%

43%

DPC Dash (SEHK:1405)

38.2%

89.7%

Zylox-Tonbridge Medical Technology (SEHK:2190)

18.5%

79.3%

Adicon Holdings (SEHK:9860)

22.3%

29.6%

Tian Tu Capital (SEHK:1973)

34%

70.5%

Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)

13.9%

100.1%

Zhejiang Leapmotor Technology (SEHK:9863)

15%

73.8%

Beijing Airdoc Technology (SEHK:2251)

27.8%

83.9%

Click here to see the full list of 52 stocks from our Fast Growing SEHK Companies With High Insider Ownership screener.

We're going to check out a few of the best picks from our screener tool.

Meitu

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Meitu, Inc. is an investment holding company specializing in image, video, and design products to promote industry digitalization with beauty-related solutions, operating both in the People’s Republic of China and internationally, with a market capitalization of approximately HK$13.65 billion.

Operations: The company generates revenue primarily through its Internet Business segment, which reported earnings of CN¥2.70 billion.

Insider Ownership: 38%

Meitu, a company with substantial insider ownership in Hong Kong, recently enhanced its governance structure and dividend policy, reflecting strong internal confidence. Despite a backdrop of executive changes, Meitu's financial health appears robust with significant earnings growth outpacing market averages. However, its revenue growth projections are modest compared to some peers. The company trades well below estimated fair value, suggesting potential undervaluation amidst these positive developments.

SEHK:1357 Ownership Breakdown as at Jun 2024

Alibaba Health Information Technology

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Alibaba Health Information Technology Limited operates as an investment holding company, focusing on pharmaceutical direct sales, e-commerce platforms, and healthcare and digital services in Mainland China and Hong Kong, with a market cap of approximately HK$62.07 billion.